The experimental cancer drug ibrutinib has wowed in clinical trials, beating deadly blood cancers without the painful side effects of currently approved therapies.
And it has raced through development and regulatory hurdles, in part thanks to a US program to accelerate the development of particularly promising drugs, says its developer Pharmacyclics, based in Sunnyvale, California.
The US Food and Drug Administration (FDA) launched the ‘breakthrough therapy’ designation in 2012, and the label has been eagerly embraced by the pharmaceutical industry. Recent months have seen a steady stream of drugs being submitted for review. For some firms — particularly young ones — the designation can bring an extra boost of cash by raising investor confidence.
But for all the fanfare, the industry is also watching closely to see exactly what benefits can be gained by having a drug reviewed through this route. “It’s like winning a beauty pageant,” says Timothy Coté, a former director of the FDA’s Office of Orphan Products Development who now runs a consultancy called Coté Orphan Consulting in Silver Spring, Maryland. “It doesn’t have specific tangible outcomes, but it does appear to have enlivened the community.”
The breakthrough therapy designation was created by the FDA Safety and Innovation Act, a law that requires the agency to fast-track promising drugs for serious or life-threatening conditions. The FDA aims to do this by meeting early and often with developers, as well as working with them to design clinical trials that deliver the needed data quickly and efficiently.
The industry leapt on the opportunity, so far submitting 99 applications for the designation. But the flurry of applications may partly be a product of confusion, says Coté: the FDA has avoided laying out detailed descriptions of what constitutes a breakthrough, and some companies are unsure of the criteria. “Most biotech chief executives with something in the clinic think that they’re already there,” Coté says — but 47 of the applications submitted in the past year have been denied. In most cases the denials are due to insufficient clinical data, the FDA says.
The Latest on: Fast-Track Drugs
- BioXcel Dips on FDA Fast Track on December 29, 2018 at 1:22 am
The New Haven-based BioXcel said FDA's Fast Track program is designed to provide certain benefits for new drugs that treat serious or life-threatening conditions and demonstrate the potential to ... […]
- BioXcel Surges on Fast Track Designation to Agitation Drug on December 28, 2018 at 2:34 pm
Shares of clinical-stage biopharmaceutical company, BioXcel Therapeutics, Inc. BTAI surged significantly after the FDA granted Fast Track designation to its experimental drug, BXCL501. BXCL501, a ... […]
- Treatment for Acute Agitation Gets Fast Track Designation on December 28, 2018 at 9:56 am
The Food and Drug Administration (FDA) has granted Fast Track designation to BXCL501 (BioXcel Therapeutics [BTI]), an investigational treatment for acute agitation. Dexmedetomidine as a solution for i... […]
- BioXcel’s agitation drug gets FDA Fast Track on December 28, 2018 at 2:06 am
The FDA has granted Fast Track Designation to BioXcel Therapeutics’ BXCL501 for the treatment of acute agitation resulting from neurological and psychiatric disorders like Alzheimer’s and ... […]
- BTAI On Fast Track, ERYP Faces Busy Year Ahead, CHMA Turning Heads on December 27, 2018 at 7:43 am
News: The Company's investigational drug BXCL501, a proprietary sublingual film of dexmedetomidine, has been granted Fast Track Designation by the FDA for the treatment of acute agitation. BXCL501 is ... […]
- BioXcel +15% on Fast Track designation on December 27, 2018 at 5:40 am
BioXcel's (NASDAQ:BTAI) investigational drug BXCL501 - a proprietary sublingual film of dexmedetomidine, for the treatment of acute agitation - has been granted Fast Track Designation by the FDA. […]
- BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation on December 27, 2018 at 5:00 am
FDA's Fast Track program is designed to provide certain benefits for new drugs that treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. […]
- Roche May Have A Competing Drug For A Rare Disease on December 26, 2018 at 6:42 pm
The drug used in a late-stage study known as satralizumab ... For starters, the most important item is an expedited review time. This includes Fast Track Designation, along with more frequent ... […]
- 18 of the Worst Drug Recalls in History on December 26, 2018 at 12:48 pm
Some of the drugs on our list of recalls were approved after 1988 when the government allowed a “fast track” approval process to make medications aimed at treating serious and life-threatening conditi... […]
- VALNEVA Awarded FDA Fast Track Designation for Chikungunya Vaccine Candidate on December 21, 2018 at 8:46 am
Fast Track is designed to facilitate the clinical development and expedite the review of new drugs and vaccines with the intention of accelerating the availability of promising products on the ... […]
via Google News and Bing News